ANTIDEPRESSANTS IN ANXIETY DISORDERS--DISCONTINUATION/MAINTENANCE W/ IMIPRAMINE

焦虑症中的抗抑郁药——停药/用丙咪嗪维持治疗

• 批准号: 6276565
• 负责人: MATIG R MAVISSAKALIAN
• 金额: $ 1.83万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6276565
• 关键词: agoraphobia; behavioral /social science research tag; clinical research; drug screening /evaluation; drug withdrawal; human subject; human therapy evaluation; imipramine; longitudinal human study; mental disorder chemotherapy; panic disorder; placebos; relapse /recurrence; tricyclic antidepressant

The main objectives of the study are a) to assess the extent of worsening/relapse upon discontinuation of imipramine and to test the hypothesis that maintenance on the drug protects from such reversal in a total experimental sample of 100 subjects with Panic Disorder and Agoraphobia who have shown good and stable response to 6 months of systematic open treatment prior to randomization to the 12 month prospective placebo controlled discontinuation/maintenance phase of the study; b) An evaluation of late relapse/reversals achieved by extending the observation period of the double-blind placebo substitution condition to 24 months; c) A controlled assessment of relapse within the 12 month period following discontinuation of 1 year maintenance treatment d) A follow-up for 3 to 4 years from initial randomization of study completers and relapsers who are retreated as well as subjects who drop out from various stages of the double-blind protocol in order to gather systematic longitudinal and clinically relevant data specifically as they relate to relapse after varying lengths of imipramine maintenance treatment.

这项研究的主要目的是：a)评估 停用丙咪嗪后病情恶化/复发，并测试 假设在药物上的维持可以防止这种逆转 100例惊恐障碍和惊恐障碍的实验样本 对6个月有良好和稳定反应的广场恐惧症患者 随机前至12个月的系统开放治疗 预期的安慰剂控制的停用/维持阶段 研究；b)对通过扩大治疗而实现的晚期复发/逆转的评价 安慰剂双盲替代的观察期 将病情延长至24个月；c)在以下时间内对复发进行受控评估 停止1年维持后的12个月期间 治疗d)从最初的随机化开始，随访3至4年 研究完成者和复吸者以及受试者的比例 他们按顺序退出了双盲方案的各个阶段 收集系统的纵向和临床相关数据 特别是因为它们与不同长度的 丙咪嗪维持治疗。